Among the prognostic biomarkers involved in the GBM-specific CeRNA and PPI network, the most significant difference gene was PLAU (encoding urokinase-type plasminogen activator; uPA), which was overexpressed, was the target of lncRNA H19, and was enriched in the KEGG pathway, namely, MicroRNAs in cancer, NF-kappa B signaling pathway, transcriptional misregulation in cancer, and proteoglycans in cancer pathways. This evidence concerns the gene PLAU and glioblastoma.